SynthesisFrontiers in oncology2025
Utility and clinical effectiveness of liquid biopsy-based DNA methylation testing in early tumor screening and diagnosis, emphasizing older adult populations: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global aging population faces a disproportionate burden of lung cancer, creating an urgent need for minimally invasive screening methods. Liquid biopsy-based DNA methylation testing, particularly targeting the cysteine dioxygenase type 1 (CDO1) gene promoter, has emerged as a promising approach for early cancer detection. This study aims to systematically evaluate the diagnostic value of CDO1 promoter methylation in lung cancer using liquid biopsies. Methods: A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library from inception to 28Th September, 2025. Studies reporting CDO1 promoter methylation in liquid biopsies (blood, urine, or sputum) for lung cancer detection with histological confirmation were included. Methodological quality was assessed using QUADAS-2. Bivariate random-effects models were used to calculate pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive/negative likelihood ratios (PLR/NLR), and 95% confidence intervals. Results: Seven studies involving 655 lung cancer cases and 402 controls were included. CDO1 methylation demonstrated pooled sensitivity of 0.72 and specificity of 0.89 for blood-based liquid biopsies, and 0.66 and 0.87 for non-blood specimens, respectively. The overall diagnostic odds ratio was 19.13 (95% CI: 13.53-26.84), with positive and negative likelihood ratios of 7.73 (95% CI: 5.77-10.35) and 0.32 (95% CI: 0.26-0.39). No significant heterogeneity was observed across studies (I² = 0% for all parameters). Subgroup analyses revealed consistent performance across different specimen types and geographic regions. Conclusion: CDO1 promoter methylation detection in liquid biopsies shows robust diagnostic accuracy for lung cancer, with performance characteristics supporting its potential clinical utility, particularly for older populations who face barriers to conventional screening. The consistency across diverse specimen types and populations underscores its promise as a minimally invasive screening tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.